Antonello Mai

发表

Epi‐Informatics: Discovery and Development of Small Molecule Epigenetic Drugs and Probes. Edited by José Medina‐Franco

Antonello Mai, 2017 .

Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches

Rino Ragno, Alexandros Patsilinakos, Antonello Mai, 2018, Journal of Computer-Aided Molecular Design.

Epigenetic Pharmacology in Regenerative Medicine (Epi-Drugs)

Giulia Stazi, Antonello Mai, Clemens Zwergel, 2019, Epigenetics and Regeneration.

Histone Deacetylase Inhibitors: Structure-Based Modeling and Isoform-Selectivity Prediction

Garland R. Marshall, Rino Ragno, Flavio Ballante, 2012, J. Chem. Inf. Model..

Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies.

Silvio Massa, Rino Ragno, Silvia Simeoni, 2008, European journal of medicinal chemistry.

Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.

Lucia Altucci, Antonello Mai, L. Altucci, 2009, The international journal of biochemistry & cell biology.

Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

Satoshi Inoue, Antonello Mai, G. Cohen, 2006, Cancer research.

Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.

Rino Ragno, Flavio Ballante, Roberto Cirilli, 2014, Journal of medicinal chemistry.

Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors

Yun Song, Mingxuan Wu, Jeffrey J Gray, 2018, Nature Communications.

3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole-C2 and/or -C4 Substitutions on Biological Activity†

Silvio Massa, Rino Ragno, Antonello Mai, 2004 .

Inhibition of Class I Histone Deacetylases Unveils a Mitochondrial Signature and Enhances Oxidative Metabolism in Skeletal Muscle and Adipose Tissue

Antonello Mai, Alice Gualerzi, Dante Rotili, 2013, Diabetes.

2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.

Ira Musmuca, Rino Ragno, Flavio Ballante, 2012, Journal of medicinal chemistry.

Targeting Lysine Deacetylases (KDACs) in Parasites

Garland R. Marshall, Bruce A. Rosa, Makedonka Mitreva, 2015, PLoS neglected tropical diseases.

HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.

Gordon B Mills, Euan A Stronach, Antonello Mai, 2011, Cancer research.

Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant.

Silvio Massa, Rino Ragno, Gianluca Sbardella, 2004, Journal of medicinal chemistry.

Histone deacetylation in epigenetics: An attractive target for anticancer therapy

Silvio Massa, Rino Ragno, Silvia Simeoni, 2005, Medicinal research reviews.

Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation.

Silvio Massa, Rino Ragno, Gianluca Sbardella, 2002, Journal of medicinal chemistry.

3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures.

Silvio Massa, Rino Ragno, Antonello Mai, 2003, Journal of medicinal chemistry.

An Introduction to Medicinal Chemistry 4th ed.

Paolo Tortorella, A Macchiarulo, Antonello Mai, 2010 .

Slow‐, Tight‐Binding HIV‐1 Reverse Transcriptase Non‐Nucleoside Inhibitors Highly Active against Drug‐Resistant Mutants

Gianluca Sbardella, Antonello Mai, Imma Clotet-Codina, 2007, ChemMedChem.

HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.

Euan A Stronach, Antonello Mai, Bryan T Hennessy, 2011, Cancer research.

Substrate‐Induced Stable Enzyme–Inhibitor Complex Formation Allows Tight Binding of Novel 2‐Aminopyrimidin‐4(3H)‐ones to Drug‐Resistant HIV‐1 Reverse Transcriptase Mutants

Antonello Mai, Mercedes Armand-Ugón, José A. Esté, 2008, ChemMedChem.

Selective Non-nucleoside Inhibitors of Human DNA Methyltransferases Active in Cancer Including in Cancer Stem Cells

Ettore Novellino, Sandro Cosconati, Xing Zhang, 2014, Journal of medicinal chemistry.